SER-287(一种基于孢子的微生物组疗法)治疗活动性轻中度溃疡性结肠炎的1b期安全性研究
这项双盲1b期试验在58例活动性轻中度溃疡性结肠炎患者中评估SER-287的安全性与疗效。患者先接受万古霉素或安慰剂预处理6天,再接受SER-287或安慰剂8周。万古霉素后每日SER-287组第8周临床缓解率40%,高于安慰剂/安慰剂组0%(P=0.024)。
要点
- 万古霉素预处理后每日SER-287组临床缓解率40%,安慰剂/安慰剂组0%(P=0.024)。
- 不良事件比例在各组间无显著差异。
- 万古霉素预处理和每日给药促进SER-287菌种定植。
核心结论
- 在这项短期小样本1b期试验中,SER-287的安全性和耐受性与安慰剂相似。
- 万古霉素后使用SER-287在诱导活动性轻中度溃疡性结肠炎缓解方面显著优于安慰剂。
- 万古霉素预处理和每日给药促进剂量菌种的定植。
研究设计与样本
- 双盲1b期试验纳入58例活动性轻中度溃疡性结肠炎成人患者,改良Mayo评分4-10、内镜子评分≥1。
- 患者先接受6天口服万古霉素125 mg每日4次或安慰剂预处理,随后接受8周口服SER-287或安慰剂。
- 患者按2:3:3:3随机分配至安慰剂后安慰剂、安慰剂后SER-287每周一次、万古霉素后SER-287每周一次或万古霉素后SER-287每日一次组。
主要发现
- 不良事件比例在各组间无显著差异。
- 万古霉素/每日SER-287组第8周临床缓解率40%,安慰剂/安慰剂组0%、安慰剂/每周SER-287组13.3%、万古霉素/每周SER-287组17.7%(万古霉素/每日SER-287组 vs 安慰剂/安慰剂组 P=0.024)。
- 第7天时所有SER-287组粪便中检出的SER-287剂量菌种数均高于安慰剂组(P<0.05),但安慰剂/每周SER-287组该差异在第7天后未维持。
- 万古霉素组在第10天及此后至给药后4周的所有时间点粪便中检出的剂量菌种数均多于安慰剂组(P<0.05)。
- 每日SER-287组第7天和第10天粪便中检出的SER-287剂量菌种数多于每周SER-287组(P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文称本研究为小样本1b期试验,且持续时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of patients with ulcerative colitis (UC). In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER-287, an oral formulation of Firmicutes spores, and the effects of vancomycin preconditioning on expansion (engraftment) of SER-287 species in the colon. METHODS: We conducted a double-blind trial of SER-287 in 58 adults with active mild-to-moderate UC (modified Mayo scores 4-10, endoscopic subscores ≥1). Participants received 6 days of preconditioning with oral vancomycin (125 mg, 4 times daily) or placebo followed by 8 weeks of oral SER-287 or placebo. Patients were randomly assigned (2:3:3:3) to groups that received placebo followed by either placebo or SER-287 once weekly, or vancomycin followed by SER-287 once weekly, or SER-287 once daily. Clinical end points included safety and clinical remission (modified Mayo score ≤2; endoscopic subscores 0 or 1). Microbiome end points included SER-287 engraftment (dose species detected in stool after but not before SER-287 administration). Engraftment of SER-287 and changes in microbiome composition and associated metabolites were measured by analyses of stool specimens collected at baseline, after preconditioning, and during and 4 weeks after administration of SER-287 or placebo. RESULTS: Proportions of patients with adverse events did not differ significantly among groups. A higher proportion of patients in the vancomycin/SER-287 daily group (40%) achieved clinical remission at week 8 than patients in the placebo/placebo group (0%), placebo/SER-287 weekly group (13.3%), or vancomycin/SER-287 weekly group (17.7%) (P = .024 for vancomycin/SER-287 daily vs placebo/placebo). By day 7, higher numbers of SER-287 dose species were detected in stool samples from all SER-287 groups compared with the placebo group (P < .05), but this difference was not maintained beyond day 7 in the placebo/SER-287 weekly group. In the vancomycin groups, a greater number of dose species were detected in stool collected on day 10 and all subsequent time points through 4 weeks post dosing compared with the placebo group (P < .05). A higher number of SER-287 dose species were detected in stool samples on days 7 and 10 from subjects who received daily vs weekly SER-287 doses (P < .05). Changes in fecal microbiome composition and metabolites were associated with both vancomycin/SER-287 groups. CONCLUSIONS: In this small phase 1b trial of limited duration, the safety and tolerability of SER-287 were similar to placebo. SER-287 after vancomycin was significantly more effective than placebo for induction of remission in patients with active mild to moderate UC. Engraftment of dose species was facilitated by vancomycin preconditioning and daily dosing of SER-287. ClinicalTrials.gov ID NCT02618187.
引用
- Henn MR, O'Brien EJ, Diao L, et al. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis. Gastroenterology. 2020. PMID: 32763240. doi:10.1053/j.gastro.2020.07.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。